SR

Sapnaben Riteshbhai Nayta

Active Director Additional Director DIN 11258624
DIN 11258624 First appointment Oct 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Sapnaben Riteshbhai Nayta

Data last updated:

Sapnaben Riteshbhai Nayta is an Additional Director at Glimpus Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 11258624
Primary Designation Additional Director
Industry Pharma
First Appointment 14 Oct 2025

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Additional Director14 Oct 2025Active

Board colleagues of Sapnaben Riteshbhai Nayta

NameDINCompanyDesignation
Mitesh Ghodawat09674446Glimpus Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Glimpus Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sapnaben Riteshbhai Nayta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sapnaben Riteshbhai Nayta

Sapnaben Riteshbhai Nayta currently holds 1 directorship: Glimpus Pharmaceuticals Private Limited (Additional Director, since 14 Oct 2025).

Sapnaben Riteshbhai Nayta was first appointed on 14 Oct 2025 as Additional Director at Glimpus Pharmaceuticals Private Limited.

The current boards of Sapnaben Riteshbhai Nayta's companies include Mitesh Ghodawat (Glimpus Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available